A Phase I/II Study of the Combination of BKM120 and Bevacizumab, Glioblastoma Multiforme

Diseases and Conditions Researched

Brain and Nervous System

What is the purpose of this trial?

Primary Objective Phase I
To establish the optimal dose of BKM120 that can be administered in combination with a standard dose of bevacizumab.
Primary Objective Phase II
To evaluate the efficacy of the BKM120/bevacizumab combination in patients with relapsed/refractory GBM. For evaluation of efficacy, patients previously treated with bevacizumab will be considered separately from those with no previous bevacizumab treatment.

Participation Guidelines

Age: 18 Years and older
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: Sarah Cannon Research Institute Oncology Research Consortium
Last Updated:
Study HIC#: 1203009888